In a SUNY Upstate study shown at ACG 2026, tirzepatide users had the biggest drop. The authors say prospective trials are still needed to prove a protective effect.
Recap by typeshit. Full story at Gastroenterology Advisor.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
An investor account posts the figure with no study, trial or source named. Treat it as an unverified claim until data backs it up.
One man told CNN he lied on intake forms and was hospitalized with organ failure. Eating disorder clinicians say they are seeing sharp rises in cases like his.
Loading…